What Spedra Treats: Main Uses and Benefits

Spedra (active substance Avanafil) is commonly used for managing Erectile Dysfunction (ED), which is when adult men are unable to achieve or keep a penile erection firm enough for satisfactory sexual activity. This therapeutic application is applied in addressing the primary symptomatic cluster of inadequate penile rigidity and erectile maintenance failure.

The core therapeutic use involves addressing the symptoms related to physical discomfort and functional stress that characterize ED. The medication helps address symptom clusters associated with ED across all severity levels—mild, moderate, or severe. It is considered relevant for managing symptoms in older adult men, those with health challenges like Diabetes Mellitus, and individuals who have undergone urologic pelvic surgery. The therapeutic intent is relevant for easing symptoms that fluctuate and supports the patient during difficult episodes by easing distress.

“The medication may assist with managing symptoms that interfere with daily functioning and contributes to improved comfort during symptomatic periods.”

Quick Fact: Support for Symptoms of Impaired Functional Rigidity
Primary Indication	Erectile Dysfunction (ED)
Symptom Focus	Inadequate penile rigidity and erection maintenance failure
Patient Groups	Older adults, men with diabetes, post-prostatectomy patients
Overall Benefit	Contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods

Regulatory References

1. European Medicines Agency product information on Spedra

Spedra is strictly indicated for use only in adult men aged 18 years and older. Use is not indicated for the pediatric population or for women, including during pregnancy or lactation. Dose adjustments are not required for older men (age 65 and above) or for men with mild to moderate renal impairment.

---

The medicine is contraindicated and must not be used by several populations due to serious health risks defined in regulatory labeling. This includes patients with severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (creatinine clearance < 30 mL/min).

Contraindications also apply to individuals with a history of recent cardiovascular events, such as a myocardial infarction or stroke within the last six months, or those with unstable angina or severe congestive heart failure (NYHA Class 2 or greater). Patients with a history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) are also prohibited from use.

Additionally, use is strictly prohibited for patients taking any form of organic nitrate medicine or strong medications known as potent CYP3A4 inhibitors. The label advises caution for men with conditions such as anatomical deformation of the penis or those predisposed to priapism.

Interactions with other medicines and products

The use of Spedra (avanafil) is strictly restricted or contraindicated with several other medications due to the potential for serious interactions documented in regulatory information.

Contraindicated Combinations

Co-administration is contraindicated with any form of organic nitrates or nitric oxide donors (such as amyl nitrite). This is because Spedra significantly augments the hypotensive effects of nitrates. Similarly, concurrent use with Guanylate Cyclase (GC) Stimulators (e.g., riociguat) is contraindicated as it may lead to symptomatic hypotension.

Administration with strong CYP3A4 inhibitors (including ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nelfinavir, and telithromycin) is also contraindicated because they substantially increase avanafil exposure.

Use-With-Caution Combinations

• Moderate CYP3A4 Inhibitors: Co-administration with these medicines (e.g., erythromycin, diltiazem, fluconazole, verapamil) requires a maximum dose restriction for Spedra, which must not exceed 50 mg every 24 hours.
• Alpha-Blockers and Other Antihypertensives: The drug may potentiate the blood pressure-lowering effects of these agents. Patients must be stable on alpha-blocker therapy prior to starting Spedra to mitigate the risk of symptomatic hypotension. The lowest Spedra dose is recommended for initial use in these stable patients.
• Alcohol: Consumption of substantial amounts of alcohol (greater than 3 units) concurrently with Spedra can increase the likelihood of symptomatic hypotension.

How Spedra Works

Avanafil, the active substance in Spedra, functions as a highly selective and reversible inhibitor of the enzyme Phosphodiesterase type 5 ( PDE5). The mechanism targets this enzyme specifically within the vascular smooth muscle cells, particularly those of the corpus cavernosum.

Mechanism and Physiological Cascade

By blocking PDE5, Avanafil prevents the degradation of the cellular messenger cyclic Guanosine Monophosphate ( cGMP). The resulting cGMP accumulation activates a downstream signaling sequence that leads to a reduction of intracellular calcium ( Ca^2+). This change in ion concentration causes the smooth muscle of the arterial walls and trabeculae to relax (vasodilation). The smooth muscle relaxation subsequently increases localized blood flow into the specific tissues, causing a change in local hemodynamics.

Mechanistic Dependency

Crucially, this entire pharmacological effect is absolutely dependent on the body’s natural production and release of Nitric Oxide ( NO), which is triggered by physiological stimulation. Avanafil’s action solely functions to prolong the activity of the cGMP molecule within the pathway, and does not initiate the smooth muscle relaxation process autonomously.

Administration Principles and Dosing

Spedra (Avanafil) is administered via the oral route as an intermittent, on-demand medication, not a fixed daily regimen. The maximum recommended frequency is once per day. For proper use, the tablet must be taken approximately 15 to 30 minutes before anticipated sexual activity. The therapeutic effect is contingent upon concurrent sexual stimulation. The tablet may be taken with or without food; however, administration with a meal may result in a delayed onset of activity.

The standard recommended starting dose is 100 mg. Based on individual patient response and tolerability, the dose may be adjusted down to a minimum of 50 mg or increased to a maximum dose of 200 mg. Standard practice involves using the lowest effective dose.

Population or Context	Dosing Rule
Older Adults (≥65 years)	No dose adjustment is typically required.
Mild to Moderate Renal/Hepatic Impairment	For mild-to-moderate hepatic impairment, the minimum efficacious dose of 50 mg should be used initially.
Concurrent Alpha-Blocker Therapy	Initiate treatment at the 50 mg dose for patients on stable alpha-blocker therapy.
Concurrent Moderate CYP3A4 Inhibitors	The maximum dose must not exceed 50 mg within a 24-hour period.

The administration schedule is strictly as-needed, which means that instructions for a missed dose are not applicable to the overall use protocol.

Research Evidence / Overview of Studies for Spedra

The research base for Spedra (Avanafil) consists primarily of formal clinical trials, which are reviewed by regulatory bodies like the European Medicines Agency (EMA). This research describes how studies monitored the patterns of change in patients' reported experiences and functional outcomes under controlled conditions. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

---

Evidence for Use in Erectile Dysfunction (ED) in the General Population

Initial research exploring how symptoms change over time used short-term, randomized controlled trials (RCTs) in adult men diagnosed with erectile dysfunction (ED). These studies were designed to compare the effects against a placebo and examined outcomes reflecting daily functioning or activity level over a period typically lasting 12 weeks.

The trials monitored specific patient-reported outcomes, which describe perceived discomfort and changes in the ability to perform sexual activity. This includes measuring the change in the International Index of Erectile Function (IIEF) score and the percentage of attempts achieving successful vaginal penetration and successful intercourse. Studies reported measurements of how functional outcomes, as assessed by these standard tools, evolved over the defined time interval.

---

Evidence in Men with ED and Specific Health Conditions

Studies also explored the use of Avanafil in men with ED who have certain underlying health issues, conditions marked by functional limitations. Separate, controlled trials were conducted to specifically research populations with Diabetes Mellitus and men who had undergone nerve-sparing radical prostatectomy for prostate cancer. These studies monitored outcomes related to functional capacity in the context of ED over short-term periods, typically 12 weeks.

In the diabetes subgroup, data show patterns related to functional measurements, but the observed outcomes were sometimes described as being of limited magnitude compared to the general population findings. For the post-prostatectomy subgroup, research described measurements for men with ED following nerve-sparing surgery. Data show patterns related to successful intercourse that were also generally lower than in the general ED population.

---

What is Still Uncertain and Key Evidence Gaps

Research has also examined experience over longer periods through unblinded, open-label extension studies (up to 52 weeks). However, long-term effects are not fully established, and there is limited information for long-term outcomes beyond the one-year mark of the extension trials. Key research limitations include the fact that comparative evidence is lacking for direct assessment against other established ED treatments. While numerous studies have been conducted, the sample sizes were modest in specific comorbid groups, meaning the certainty remains low for these complex populations.

Key Studies & References

1. Avanafil for male erectile dysfunction: a systematic review and meta-analysis

Common questions about Spedra (FAQ)

Q: What is the typical duration of effect for a single dose of Spedra?

According to official product information, the clinical effects of the medicine are generally observed to last for up to 6 hours following a single administration. This duration can vary between individuals and depends on factors such as metabolism and the specific dose taken.

Q: Is it acceptable to drink alcohol while taking Spedra?

Official product information advises that the simultaneous consumption of substantial amounts of alcohol, defined as greater than 3 units, is restricted. This is because combining the medicine with excess alcohol may potentiate the blood pressure-lowering effect. This can potentially increase the risk of symptomatic hypotension (low blood pressure).

Q: What happens if Spedra is taken with grapefruit juice?

Grapefruit juice is identified in regulatory reviews as a substance that can affect how the body processes the active ingredient, avanafil. Taking the medicine with grapefruit juice is likely to increase the amount of avanafil in your bloodstream. This increase in exposure may lead to a higher likelihood of experiencing side effects.

Q: What is priapism, and is it a reported side effect of Spedra?

Priapism (an erection lasting four hours or longer) is documented as a rare but serious adverse reaction associated with the medicine. If this occurs, immediate medical attention is required. Regulatory information notes the importance of rapid intervention to limit the potential for permanent damage.

Q: Does the risk of side effects increase with higher doses of Spedra?

Studies and official information indicate that the incidence of some common side effects is dose-dependent. Clinical trial data showed that the occurrence of common adverse reactions, such as headache and flushing, was observed to increase when a higher dose of the medicine was administered.

Q: Are there any long-term safety concerns with taking Spedra?

The research base for this medicine includes open-label extension studies that tracked patients for up to one year. Because controlled data collection ceases after this time, regulatory bodies note that the long-term safety profile of the medicine is not fully established beyond this one-year period.

Q: Why is Spedra contraindicated for people who have had a recent stroke or heart attack?

The official contraindication for men who have had a severe cardiovascular event, such as a heart attack or stroke within the last six months, relates to the potential for cardiac risk during sexual activity itself. This risk is compounded by the medicine’s action as a vasodilator, which can contribute to a drop in blood pressure.

Q: Does Spedra interact with any common antibiotics or antifungal medicines?

Yes, the medicine interacts with certain antibiotics and antifungals that belong to a class known as CYP3A4 inhibitors. Depending on whether the interacting medicine is a strong or moderate inhibitor, the use of Spedra is either prohibited or subject to a maximum dose restriction.

Q: Does Spedra help with premature ejaculation?

The therapeutic indication for Spedra is strictly limited to the management of erectile dysfunction (ED) in adult men. According to regulatory documents, the medicine is not approved, recommended, or indicated for the treatment of premature ejaculation.

Q: Does Spedra have any effect on male fertility or sperm characteristics?

Regulatory reviews, based on nonclinical findings, confirm that the potential effects of avanafil on human sperm production, known as spermatogenesis, are currently unknown. Official information does not establish whether the medicine has an impact on male fertility or sperm characteristics.

Q: What measures are recommended if Spedra does not appear to be working?

The regulatory protocol allows for dose adjustment if the starting dose is not effective. This adjustment ranges from 50 mg up to a maximum dose of 200 mg. Official information emphasizes that the goal is to establish the lowest effective dose based on individual response and tolerability.

Q: Does taking Spedra affect the ability to drive or operate machinery?

Regulatory warnings caution that the medicine may cause side effects such as dizziness or changes in vision. If these effects are experienced, official guidance stipulates that caution should be exercised regarding driving or operating complex machinery until the effects subside.

How to Store and Dispose of Spedra

Spedra (avanafil) tablets must be stored and handled according to regulatory requirements to preserve product integrity.

Storage Conditions

Requirement	Status
Temperature and Light	Generally does not require any special storage conditions.
Packaging	Must be kept in the original blister until the time of administration.
Safety	Store strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Spedra must be managed to protect the environment and prevent accidental access. The medicine must not be disposed of via wastewater or household waste. Disposal should instead follow local requirements for medicinal products, often meaning returning the product to a pharmacy or using an authorized drug take-back program.